Literature DB >> 7510984

Identification of IgE-bearing cells in the late-phase response to antigen in the lung as basophils.

C B Guo1, M C Liu, S J Galli, B S Bochner, A Kagey-Sobotka, L M Lichtenstein.   

Abstract

We have carried out studies to ascertain whether the histamine-containing, IgE-bearing cells found in the bronchoalveolar lavage (BAL) fluid obtained during the late-phase response following subsegmental antigen challenge of human airways are predominantly basophils or mast cells. Four lines of evidence suggest that most are basophils: (1) The cells fulfill morphologic criteria for light microscopy. (2) Cell surface markers determined by immunofluorescence and flow cytometry revealed that the IgE-bearing cells express the leukocyte antigens Fc gamma RII and the beta 2 integrins, LFA-1 and Mac-1, but do not express the mast cell-associated c-kit receptor for stem cell factor. (3) The late-phase histamine-containing cells in late-phase BAL fluids have the functional characteristics of basophils in their secretory responses to anti-IgE, the f-met peptide, and phorbol ester TPA. (4) The cells have a functional histamine type 2 receptor, a characteristic of basophils, not mast cells. We conclude that basophils infiltrate the lower airways hours after antigen exposure. These cells may be responsible for the mediator release observed at that time.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7510984     DOI: 10.1165/ajrcmb.10.4.7510984

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  16 in total

Review 1.  Basophils in airway disease.

Authors:  Donald MacGlashan; Gail Gauvreau; John T Schroeder
Journal:  Curr Allergy Asthma Rep       Date:  2002-03       Impact factor: 4.806

2.  Regulation of human basophil function by phosphatase inhibitors.

Authors:  M J Peirce; J A Warner; M R Munday; P T Peachell
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

Review 3.  Therapeutic approaches to asthma based on VLA-4 integrin and its counter receptors.

Authors:  W J Metzger
Journal:  Springer Semin Immunopathol       Date:  1995

4.  Characterization of Siglec-8 Expression on Lavage Cells after Segmental Lung Allergen Challenge.

Authors:  Mats W Johansson; Elizabeth A Kelly; Christopher L Nguyen; Nizar N Jarjour; Bruce S Bochner
Journal:  Int Arch Allergy Immunol       Date:  2018-06-07       Impact factor: 2.749

5.  Granulocyte-macrophage colony-stimulating factor and interleukin-3 cause basophil histamine release by a common pathway: downregulation by sodium.

Authors:  A Tedeschi; C Salmaso; M Di Donato; M Lorini; A Miadonna
Journal:  Immunology       Date:  1999-02       Impact factor: 7.397

6.  IgG Autoantibodies Against IgE from Atopic Dermatitis Can Induce the Release of Cytokines and Proinflammatory Mediators from Basophils and Mast Cells.

Authors:  Remo Poto; Isabella Quinti; Gianni Marone; Maurizio Taglialatela; Amato de Paulis; Vincenzo Casolaro; Gilda Varricchi
Journal:  Front Immunol       Date:  2022-05-31       Impact factor: 8.786

7.  Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia.

Authors:  Michel Laviolette; David L Gossage; Gail Gauvreau; Richard Leigh; Ron Olivenstein; Rohit Katial; William W Busse; Sally Wenzel; Yanping Wu; Vivekananda Datta; Roland Kolbeck; Nestor A Molfino
Journal:  J Allergy Clin Immunol       Date:  2013-07-16       Impact factor: 10.793

8.  Inflammatory mechanisms in the lung.

Authors:  B Moldoveanu; P Otmishi; P Jani; J Walker; X Sarmiento; J Guardiola; M Saad; Jerry Yu
Journal:  J Inflamm Res       Date:  2008-12-16

9.  An immunoglobulin E-dependent recombinant histamine-releasing factor induces interleukin-4 secretion from human basophils.

Authors:  J T Schroeder; L M Lichtenstein; S M MacDonald
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

10.  MHC class II expression in human basophils: induction and lack of functional significance.

Authors:  Astrid L Voskamp; Sara R Prickett; Fabienne Mackay; Jennifer M Rolland; Robyn E O'Hehir
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.